NCT01627106 - A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055) | Biotech Hunter

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions

Atrial Fibrillation

Interventions

DRUG

Vernakalant

Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.

DRUG

Amiodarone

Administered IV as per product label